KEMEYA Drug Patent Profile
✉ Email this page to a colleague
When do Kemeya patents expire, and when can generic versions of Kemeya launch?
Kemeya is a drug marketed by Sun Pharm and is included in one NDA.
The generic ingredient in KEMEYA is drospirenone; ethinyl estradiol. There are eleven drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the drospirenone; ethinyl estradiol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Kemeya
A generic version of KEMEYA was approved as drospirenone; ethinyl estradiol by DR REDDYS LABS SA on September 7th, 2010.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for KEMEYA?
- What are the global sales for KEMEYA?
- What is Average Wholesale Price for KEMEYA?
Summary for KEMEYA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | KEMEYA at DailyMed |
US Patents and Regulatory Information for KEMEYA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm | KEMEYA | drospirenone; ethinyl estradiol | TABLET;ORAL-28 | 202138-001 | Mar 13, 2019 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
